A5003408994- Rheumatoid Arthritis Research and Therapies
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Toxin Mechanisms and Immunotoxins
- Autoimmune and Inflammatory Disorders Research
- Lymphoma Diagnosis and Treatment
McMaster University
2020-2024
University of Saskatchewan
2020
University of Toronto
2020
Université de Montréal
2020
Memorial University of Newfoundland
2020
Keystone College
2020
Upadacitinib (UPA), a selective, reversible, oral Janus kinase (JAK)-1 inhibitor, was approved in 2019 Canada for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). This phase 4 prospective study aimed characterise effectiveness UPA real-world population patients RA. Adults RA who initiated once daily (15 mg) and enrolled Canadian Real-Life post-marketing Observational Study assessing Effectiveness UPadacitinib treating (CLOSE-UP) completed 6-month...
Abstract Background Long-term clinical registries are essential tools to evaluate new therapies in a patient population that differs from those randomized trials. The objectives describe the profile of rheumatoid arthritis (RA) patients treated with anti-TNF agents Canadian routine care. Methods RA eligible for treatment Infliximab (IFX), golimumab (GLM) or intravenous (GLM-IV) as per their respective product monographs were enrolled into BioTRAC registry between 2002 and 2017. Study visits...
Abstract Background : Long-term clinical registries are essential tools to evaluate new therapies in a patient population that differs from those randomized trials. The objectives describe the profile of rheumatoid arthritis (RA) patients treated with anti-TNF agents Canadian routine care. Methods RA eligible for treatment Infliximab (IFX), golimumab (GLM) or intravenous (GLM-IV) as per their respective product monographs were enrolled into BioTRAC registry between 2002 and 2017. Study...